Poxvirus Infections Pipeline Report, H1 2016 - Review of China Biologic Products, Inc. & SIGA Technologies, Inc. and their Drug Profiles - Research and Markets

Research and Markets has announced the addition of the "Poxvirus Infections - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Poxvirus Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Poxvirus Infections Overview
3. Therapeutics Development
4. Pipeline Products for Poxvirus Infections - Overview
5. Pipeline Products for Poxvirus Infections - Comparative Analysis
6. Poxvirus Infections - Therapeutics under Development by Companies
7. Poxvirus Infections - Therapeutics under Investigation by Universities/Institutes
8. Poxvirus Infections Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Poxvirus Infections - Products under Development by Companies
13. Poxvirus Infections - Products under Investigation by Universities/Institutes
14. Poxvirus Infections - Companies Involved in Therapeutics Development

• China Biologic Products, Inc.
• SIGA Technologies, Inc.

For more information visit http://www.researchandmarkets.com/research/ntg7st/poxvirus

View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005678/en/